CBLL - CeriBell, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

CBLL

CERIBELL, INC.

NASDAQ

$23.63

▲ UP 2.07% (0.48)

KEY STATISTICS

Market Cap$884.25 M

52w High$25.63

52w Low$10.85

Dividend Yield—

Frequency—

P/E-13.43

Volume243.73K

Shares Out.37.94M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Xingjuan Chao

COMPENSATION 2026

Salary$639,000

Stock Awards$1,707,132

Incentive Plan Pay$619,313

All Other Comp.$26,197

Total$4,565,821

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 11, 2024

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

327

PRICE TARGET

Target High$29.00

Target Low$26.00

Target Median$27.50

Target Consensus$27.50

UPCOMING EARNINGS

DateNov 3, 2026

DayTuesday

Rev. Est.$29.17M

NOV

TUE

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

50.00%

HOLDERS

167

TOP 8 OF 167 · RANKED BY POSITION SIZE

Red Tree Management, LLC

Bank Of New York Mellon Corp

1.2M sh

$26.8M

Abg-Wtt Global Life Science Capital Partners Gp Ltd

1.1M sh

$12.5M

PRICE

$23.63 ▲ UP 2.07% (+$0.48)

About CeriBell, Inc.

https://ceribell.com ↗

CeriBell, Inc. develops AI-powered point-of-care EEG technology, including the Ceribell System and disposable headbands, to improve detection and treatment of neurological conditions in acute care settings.

INDUSTRY

Medical - Devices

A PRODUCT CERIBELL, INC. IS KNOWN FOR

Ceribell System

Ceribell System is a portable, AI-powered EEG platform for rapid diagnosis and monitoring of neurological conditions like seizures and stroke in acute care, enabling quick assessment and recently receiving FDA Breakthrough Designation.

COMPETITORS

COMPETITOR

NMTC COMPARE

NPCE COMPARE

CeriBell in 2025

SENTIMENT: − NEGATIVE

EARNINGS · AUGUST 5, 2025

CeriBell's Strong Revenue Growth in Q2 2025 Report Overshadowed by Increased Net Loss, Leading to Significant Stock Drop

On August 5, 2025, CeriBell, Inc. announced its second-quarter financial results, reporting a 38% year-over-year revenue increase to $21.2 million and raising its full-year revenue guidance. However, the company also reported a higher net loss of $13.6 million, up from $8.9 million in the same period of the prior year, primarily due to a 56% increase in operating expenses. The market reacted negatively to the increased losses, resulting in a significant single-day drop in the company's stock price and high trading volume.

MARKET EXPANSION · THROUGHOUT 2025 · IN PROGRESS

CeriBell Executes Strategic Expansion into New Patient Populations and Clinical Applications with Multiple FDA Clearances in 2025

In 2025, CeriBell, Inc. made a significant strategic shift by successfully expanding its addressable market beyond adult seizure detection. The company actively pursued and received multiple FDA 510(k) clearances for its technology, including for pediatric and neonatal seizure detection and a first-of-its-kind delirium monitoring solution, fundamentally broadening its product's clinical applications and growth potential.